Back to top

ALNY Maintains Rating by Truist Securities -- Price Target Lowered to $410

ALNY Maintains Rating by Truist Securities -- Price Target Lowered to $410

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Alnylam Pharmaceuticals, Inc. (ALNY)